June 10, 2026 6:00 AM Eastern Daylight Time

MTTI Highlights Clinical Experience in 81 GEP-NETs Patients and Differentiated Profile of Next-Generation PRRT Candidate EBTATE Following Presentation at SNMMI 2026

Share

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage radiopharmaceutical company developing next-generation albumin-binding targeted radiotherapeutics, today announced updated clinical findings from patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with its lead investigational product candidate, **^{177}Lu-DOTA-EB-TATE (EBTATE)**, following presentation at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.

The 81-patient experience represents one of the largest clinical datasets reported to date for an albumin-binding peptide receptor radionuclide therapy (PRRT) and provides growing evidence that EBTATE may offer a differentiated and potentially best-in-class profile compared with conventional PRRT approaches.

Key Clinical Highlights from 81 Treated GEP-NET Patients

- **Approximately 8-fold higher tumor uptake** compared with conventional PRRT
- **50% objective response rate (ORR)**
- **100% disease control rate (DCR)**
- **36-month median progression-free survival (PFS)**
- **No observed kidney toxicity through one year of follow-up**
- **Equivalent renal absorbed dose with or without amino acid infusion**
- **Potential two-cycle treatment regimen** versus the conventional four-cycle PRRT

- Clinical activity achieved using only approximately **12.5% of the cumulative radioactivity administered in current standard-of-care PRRT**

The findings further validate MTTI's proprietary **Evans Blue (EB)** technology platform, which utilizes **reversible albumin binding** to extend circulation time, enhance tumor uptake, and increase tumor retention. Preclinical studies have demonstrated up **to 26-fold higher tumor** retention compared with conventional radiopharmaceutical approaches, supporting broad applicability across multiple radionuclides, targeting vectors, and tumor types.

"The clinical experience in 81 patients validates both EBTATE and the broader Evans Blue platform," said **Chris Pak, Chairman and Chief Executive Officer of MTTI.** "By improving tumor delivery and retention while requiring only approximately **12.5%** of the cumulative radioactivity administered in current standard-of-care PRRT, the platform has the potential to enhance the therapeutic index of radiopharmaceuticals across multiple cancers and with both beta- and alpha-emitting radionuclides. The combination of enhanced tumor uptake, prolonged tumor retention, favorable clinical responses, and robust safety observations supports the continued development of EBTATE and highlights the broader potential of the Evans Blue platform to improve targeted radiotherapeutics across a wide range of solid tumors."

"EBTATE achieved markedly higher tumor uptake and longer tumor retention than conventional ^{177}Lu-DOTATATE while maintaining a favorable safety profile," said **Lisa Bodei, MD, PhD**, a nuclear medicine physician at Memorial Sloan Kettering Cancer Center and recipient of the **2026 Castle Connolly America's Top Doctor Award**. "The ability to deliver higher radiation doses to tumors with significantly lower administered radioactivity highlights the potential of this albumin-binding approach to improve the therapeutic index of PRRT. This data from NET patients supports continued clinical development and further evaluation of a streamlined treatment regimen."

About Molecular Targeting Technologies, Inc.

Molecular Targeting Technologies, Inc. (MTTI) is a clinical-stage radiopharmaceutical company developing **next-generation albumin-binding targeted radiotherapeutics** for cancer. Powered by its proprietary Evans Blue (EB) technology platform, MTTI is advancing a pipeline of beta- and alpha-emitting radiopharmaceuticals designed to improve tumor targeting, increase therapeutic index, and enhance treatment efficiency. In addition to EBTATE, MTTI is

developing **^{225}Ac-EBTATE** for small cell lung cancer, where preclinical studies have demonstrated comparable efficacy to ^{225}Ac-DOTATATE at approximately 40% of the administered dose.

For more information, visit www.mtarget.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the potential safety, efficacy, clinical benefits, development plans, and commercial opportunities of EBTATE and MTTI's Evans Blue technology platform. Actual results may differ materially from those indicated by such forward-looking statements. EBTATE is an investigational product candidate that has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.

Contacts

Chris Pak
Chairman and Chief Executive Officer
Molecular Targeting Technologies, Inc.
cpak@mtarget.com